

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

Attachment 6
September 29, 2026

【Therapeutic category】 Other antitumor agents
【Non-proprietary name】 Osimertinib mesilate
【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
8. IMPORTANT PRECAUTIONS Thrombocytopenia, neutropenia, leukopenia, <u>or</u> anemia may occur. Blood tests including complete blood counts, differential white blood cell counts, etc., should be performed prior to and periodically during administration of this drug, and patients should be carefully monitored.	8. IMPORTANT PRECAUTIONS Thrombocytopenia, neutropenia, leukopenia, anemia, <u>or aplastic anemia</u> may occur. Blood tests including complete blood counts, differential white blood cell counts, etc., should be performed prior to initiation of treatment and periodically during treatment, and patients should be carefully monitored.
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions Thrombocytopenia, neutropenia, leukopenia, anemia	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions Thrombocytopenia, neutropenia, leukopenia, anemia, <u>aplastic anemia</u>

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.